Skip to main content
. Author manuscript; available in PMC: 2021 Feb 20.
Published in final edited form as: Nat Neurosci. 2020 Aug 10;23(9):1079–1089. doi: 10.1038/s41593-020-0686-7

Figure 5: The NMDA-dependent component of functional hyperemia is selectively suppressed in tau mice.

Figure 5:

A. Neocortical superfusion with the NMDAR antagonist MK-801 (10 μM) attenuates the CBF increase evoked by whisker stimulation in 2-3 months old WT and not in PS19 and rTg4510 mice, whereas superfusion with the Na+ channel blocker TTX (3 μM) attenuates the response in all groups. a=0.0003, b=0.0055, and c=0.0015 vs PS19 no treatment; d=0.0014, e=0.0180, and f=0.0052 vs PS19 MK-801; N=6 for WT in whisker stimulation; N=5 for the rest; two-way ANOVA and Tukey’s test. B. The increase in CBF produced by topical application of NMDA (40 μM) is attenuated in PS19 and rTg4510, compared to WT mice. MK-801 attenuates the CBF increase in WT, but not in PS19 and rTg4510 mice. TTX has no effects both in both WT and rTg4510 mice. N=5/group; two-way ANOVA and Tukey’s test. C. The CBF increase produced by topical application of AMPA (10 μM) is comparable in WT, PS19, and rTg4510 mice, and is not affected by MK-801 or TTX. N=6 for MK-801- & TTX-treated WT in AMPA; N=5 for the rest. Data are presented as mean±SEM. See Source Data 3 for statistical parameters.